Medtronic InSync ICD Gains Panel Support In Tiebreaking 6-5 Vote
This article was originally published in The Gray Sheet
Executive Summary
The recommended post-market requirement for Medtronic's InSync ICD and its pacing counterpart suggests that companies that conduct pivotal studies with a small number of patients will be expected to follow up with a large trial
You may also be interested in...
JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies
An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology
JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies
An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology
“Underpowered” Trials Unethical Unless In Early Phase Or Meta-Study – JAMA
Early-phase, "underpowered" clinical trials of devices or drugs can be considered ethical only if designed to guide later pivotal studies, Scott Halpern, University of Pennsylvania School of Medicine, et al., write in the July 17 Journal of the American Medical Association